Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response

Objective: We assessed the genomic profile of four representative BRCA-mutated ovarian cancer (OC) patients treated with olaparib to investigate the relationship between intratumor heterogeneity and response to olaparib treatment. The main aim is to identify possible predictive biomarkers of respons...

Full description

Bibliographic Details
Main Authors:	Elisena Franzese, Sara Centonze, Anna Diana, Angela Lombardi, Francesca Carlino, Luigi Pio Guerrera, Ferdinando De Vita, Michele Caraglia, Sandro Pignata, Fortunato Ciardiello, Michele Orditura
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-11-01
Series:	Frontiers in Oncology
Subjects:	ovarian cancer genomic profiles BRCA 1/2 mutation carriers promoter methylation olaparib (Lynparza™)
Online Access:	https://www.frontiersin.org/article/10.3389/fonc.2019.01289/full

Similar Items

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
by: Francesco Schettini, et al.
Published: (2021-06-01)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
by: Li X, et al.
Published: (2021-04-01)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
by: Ana Beatriz Varanda, et al.
Published: (2020-07-01)

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
by: Cheng Y, et al.
Published: (2018-09-01)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
by: Na Li, et al.
Published: (2021-04-01)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
by: Elisena Franzese, et al.
Published: (2020-06-01)

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
by: Kayo Inoue, et al.
Published: (2020-05-01)

The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice
by: S V Khokhlova
Published: (2016-12-01)

Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: S V Khokhlova
Published: (2017-09-01)

Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
by: Zhan M, et al.
Published: (2020-12-01)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
by: Kazuho Nakanishi, et al.
Published: (2021-07-01)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant <i>BRCA1</i> Mutant Ovarian Cells
by: Brian T. Burgess, et al.
Published: (2020-02-01)

BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives
by: Eleonora Molinaro, et al.
Published: (2020-11-01)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
by: Yi Ma, et al.
Published: (2018-10-01)

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report
by: Rosa Montero-Macias, et al.
Published: (2021-04-01)

Izkušnje z zdravilom olaparib pri zdravljenju recidivnega epitelijskega raka jajčnikov z mutacijami v genih BRCA 1 in BRCA 2
by: Erik Škof
Published: (2021-05-01)

Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
by: Xiong F, et al.
Published: (2020-07-01)

Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain
by: Luis Cordero Puentes, et al.
Published: (2018-05-01)

Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib
by: Khwanjira Hongthong, et al.
Published: (2021-08-01)

First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
by: Tomao F, et al.
Published: (2020-07-01)

International experience of using olaparib for metastatic castration-resistant prostate cancer: literature review
by: V. B. Matveev, et al.
Published: (2021-02-01)

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy
by: Toko Kumeta, et al.
Published: (2019-10-01)

Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance
by: Rachel W Anantha, et al.
Published: (2017-04-01)

Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report
by: Pramod Kumar Julka, et al.
Published: (2020-02-01)

BRCA1 reversion mutation acquired after treatment identified by liquid biopsy
by: Paul Mayor, et al.
Published: (2017-08-01)

Practical aspects of treating relapsed BRCA-associated ovarian cancer
by: A. A. Rumyantse, et al.
Published: (2019-12-01)

PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer
by: Kristie-Ann Dickson, et al.
Published: (2021-08-01)

Olaparib in the metastatic HER2-negative breast cancer setting
by: L. G. Zhukova, et al.
Published: (2020-12-01)

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
by: Niki Karachaliou, MD, PhD, et al.
Published: (2021-03-01)

The Identification of BRCA1 and BRCA2 Mutation Carriers Using Functional Genomic Assays
by: Michel, CLAIRE S.
Published: (2008)

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
by: Angiolo Gadducci, et al.
Published: (2019-01-01)

Long-Term Follow-Up of a Female Patient Treated with Olaparib—Hope for a Long Life without Relapse?
by: Mateusz Kozłowski, et al.
Published: (2021-03-01)

A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report
by: Deqiang Wang, et al.
Published: (2021-01-01)

Defective DNA repair mechanisms in prostate cancer: impact of olaparib
by: De Felice F, et al.
Published: (2017-03-01)

Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review
by: Lisa Krassuski, et al.
Published: (2019-08-01)

Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction
by: Meixiang Sang, et al.
Published: (2019-03-01)

Development of decision aids for female BRCA1 and BRCA2 mutation carriers in Germany to support preference-sensitive decision-making
by: Sibylle Kautz-Freimuth, et al.
Published: (2021-06-01)

Gene BRCA1/2 mutation in prostate cancer patients: clinical administration aspects
by: P. V. Koposov
Published: (2016-06-01)

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials
by: Ma J, et al.
Published: (2019-04-01)